Spring­Works Ther­a­peu­tics ready to launch new­ly-ap­proved desmoid tu­mor treat­ment af­ter three-month de­lay

Spring­Works Ther­a­peu­tics won FDA ap­proval for its desmoid tu­mor treat­ment Og­siveo on Mon­day, fol­low­ing a three-month reg­u­la­to­ry hic­cup.

Desmoid tu­mors are rare but lo­cal­ly ag­gres­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER